Table 1.
Baseline characteristics
| Age (mean ± SD) | 44.19 ± 12.05 |
| Female | 93 (65.5%) |
| Duration of symptoms in months (median, IQR) | 12 (6–48) |
| NYHA (%) | |
| 1 | 1(0.7%) |
| 2 | 111(78.2%) |
| 3 | 28(19.7%) |
| 4 | 2(1.4%) |
| Atrial fibrillation | 103(72.5%) |
| LA size (%) | |
| More than 6 mm | 32 (22.5%) |
| Predominant mitral lesion (%) | |
| Mitral stenosis | 66 (46.4%) |
| LVEF (mean ± SD) | 55.95 ± 4.55 |
| Right ventricular dysfunction | |
| TAPSE < 17 mm | 62 (43.7%) |
| Pulmonary artery hypertension | |
| > 40 mmHg | 120 (84.5%) |
| RV-PA uncoupling | |
| TAPSE/PASP < 0.31 | 64 (45.1%) |
| Tricuspid annulus size (%) | |
| More than 40 mm | 33 (23.2%) |
| TAP | |
| Done | 41 (28.9%) |
| Not done | 101 (71.1) |
NYHA New York Heart Association, LA left atrium, LVEF left ventricular ejection fraction, TAPSE tricuspid annular plane systolic excursion, TAP tricuspid annuloplasty, RV right ventricle, PA pulmonary artery, PASP pulmonary artery systolic pressure